The efficacy of extended-interval dosing of omeprazole in keeping gastroesophageal reflux disease patients symptom free

Annals of Pharmacotherapy

Volumn 33, Issue 5, 1999, Pages 638-641

  Bieszk, Nella ^a   Kale Pradhan, Pramodini B ^b  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; SYMPTOMATOLOGY; TREATMENT OUTCOME;

CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; GASTROESOPHAGEAL REFLUX; HUMANS; OMEPRAZOLE;

EID: 0033023253     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18224     Document Type: Article

References (21)

1. Koppele KL, Kaplan B. Management of gastroesophageal reflux disease. J Am Pharm Assoc (Wash) 1996;NS36(suppl):16-26.
2. Keyser MS, Crawley JA, Goldberg GA, Shaw MM. Gastroesophageal reflux disease in a managed care setting: professional, facility and pharmacy charges. J Managed Care Pharm 1998;4:64-70.
3. Mossner J, Holscher AH, Herz R, Schneiders A. A double blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther 1995;9:321-6.
4. Corinaldesi R, Valentini M, Belaiche J, Colin R, Geldof H, Maier C, et al. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicenter study. Aliment Pharmacol Ther 1995;9:667-71.
5. Hatlebakk JG, Berstad A, Carling L, Svedberg LE, Unge P, Ekstrom P, et al. Lansoprazole versus omeprazole in the short term treatment of reflux oesophagitis. Scand J Gastroenterol 1993;28:224-8.
6. Mee AS, Rowley JL. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther 1995;10:757-63.
7. Astra Merck 1996 Corporate Report. Wayne, PA: Corporate Relations at Astra Merck, July 1997.
8. Product monograph. Prilosec (omeprazole). Wayne, PA: Astra Merck, 1997.
9. Eggleston AW, Huijhebaert S, Dubois D, Haycox A. Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis. Gut 1998;49:13-6.
10. Klinkenberg-Knol EC, Festen HP, Meuwissen GM. Pharmacological management of gastro-oesophageal reflux disease. Drugs 1995;49:695-710.
11. 2RA resistant esophagitis - clinical, gastrin & ECL effects for up to three years (abstract). Gastroenterol 1992; 102:A35.
12. 2RA resistant reflux esophagitis - results from 6-48 months (abstract). Gastroenterol 1993;104:A38.
13. Bank S. Daily or intermittent omeprazole requirements in the long-term treatment of erosive esophagitis: results after 2-8 years of continuous therapy (abstract). Gastroenterol 1997;112:A64.
14. Mantides A, Kioulanis J, Nastos H, Stefanides G, Dimitracopoulos A, Tzovaras G, et al. Maintenance treatment of severely complicated reflux oesophagitis with low dose of omeprazole (abstract). Gut 1994;A173.
15. Kurucar C, Sontag SJ, Schnell T. Can we predict which patients with severe gastroesophageal reflux will tolerate alternate day therapy with omeprazole (abstract)? Gastroenterol 1996;110:A165.
16. Mehta V, Gopalswamy N, Barde C. Gastroesophageal reflux on daily vs alternate day omeprazole (abstract). Gastroenterol 1994;106:A136.
17. Ladas SD, Tassios PS, Raptis SA. Alternate day omeprazole maintenance therapy for grade 2-3 reflux esophagitis (abstract). Gastroenterol 1997;112:A189.
18. Ladas SD, Tassios PS, Raptis SA. Criteria for alternate day omeprazole maintenance therapy in patients with grade 2-3 reflux esophagitis (abstract). Gastroenterol 1997;112:A189.
19. Lind T, Havelund T, Carlsson R, Eriksson G, Glise H, Junghard O, et al. The effect of omeprazole 20 mg and 10 mg daily on heartburn in patients with endoscopy negative reflux disease treated on an on-demand basis (abstract). Gastroenterol 1996;110:A178.
20. Houcke Ph, Forestier S, Glofdfain D, Guyot Ph, Helbert T, Laurent J, et al. 15 mg lansoprazole or 30 mg lansoprazole every other day in the long term treatment of erosive reflux esophagitis (abstract). Gut 1997;41(sup-pl 3):A202.
21. Roseveare C, Goggon P, Patel P, Simmons N, Kimble J, Elliot J, et al. Alternate day and prn lansoprazole in the maintenance treatment of oesophagitis (abstract). Gut 1998;42(suppl 1):A86.